Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 28517


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28517

License Grant
Pursuant to the License Agreement, the Licensee acquired the exclusive right to test, gain governmental approval of, make, have made, use, distribute and sell products designed for use in carrying out methods covered under the SCD Patent (U.S. Patent No. 5,693,671) and/or incorporating technical information provided by the licensor or by any of certain doctors affiliated with the licensor.
Field of Use
The Licensee became the exclusive worldwide Licensee of U.S. Patent No. 5,693,671, entitled L-glutamine Therapy for Sickle Cell Disease and Thalassemia to develop a treatment for SCD and Thalassemia using L-glutamine pursuant to a License Agreement.  

The Licensee is also responsible for paying all fees and costs relating to the maintenance of the SCD Patent.

IPSCIO Record ID: 3470

License Grant
The Licensor hereby grants to the Licensee, the exclusive right and license to sell the Licensed Products, to practice the Licensed Method, and to use the Technical Information.
License Property
Invention shall mean the L-glutamine therapy for sickle cell diseases and thalassemia, covered by the Patent Rights, together with any Technical Information as herein defined.

Technical Information shall mean information related to therapies and treatments for sickle cell disease and thalassemia that provide a commercial advantage.

Patent refers to rights under United States Patent No. 5,693,671, together with any reissue or reexamination that may issue therefrom.

The Licensee may sublicense.

Field of Use
Field of Use shall mean use of the Invention for treatment of sickle cell diseases and thalassemia.

IPSCIO Record ID: 26727

License Grant
The Licensor granted the Licensee an exclusive worldwide license for the manufacturing, marketing, distribution and sales of Niprisan from the government of Nigeria, for the treatment of Sickle Cell Disease (SCD).
License Property
Nicosan is our name for the non-toxic phyto-pharmaceutical product formerly named Niprisan, a nutraceutical.

Niprisan or Nix-0699, is a phytochemical ethanol/water extract of Piper guineense seeds, Pterocarpus osum stem, Eugenia caryophyllus fruit, and Sorghum bicolor leaves being tested for the treatment of Sickle-cell disease (SCD).

IPSCIO Record ID: 6985

License Grant
The Licensee became the exclusive subLicensee of US Patent No. 5,288,703 for the U.S. market.

This Sublicense includes the rights to distribute the L-glutamine treatment for the treatment of Short Bowel Syndrome under the trademark NutreStore® in the U.S., and commercially launched NutreStore® in June 2008.

License Property
The subLicense is subject to a subLicense that the Licensor holds from Ares Trading, S.A., and if the Ares License is terminated for any reason, then our subLicense will also terminate.
Field of Use
The rights granted apply to the mammal industry relating to gut absorption.

IPSCIO Record ID: 44335

License Grant
The company executed an agreement with the University,  for an exclusive license to those rights the University may own in certain patents and patent applications relating to GBT440 and GBT440 analogs.
License Property
Product candidate, GBT440, is being developed as a once-daily, oral therapy for sickle cell disease, or SCD, and currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that we characterize as a Phase 1/2 clinical trial. GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its associated symptoms. In addition to GBT440 for the treatment of SCD, we are leveraging our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis, and hereditary angioedema, or HAE.
Field of Use
This Agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.